Oregon Health & Science University

Oregon Health & Science University, a state-controlled academic medical center and research institution headquartered in Portland, Oregon, operates as a prime contractor and recipient on federal grants, delivering specialized clinical services, biomedical research, and advanced diagnostic and laboratory support across the Department of Veterans Affairs, National Institutes of Health, Agency for Healthcare Research and Quality, and multiple other civilian and defense agencies. OHSU does not compete under small-business set-asides; the institution is a public university and operates exclusively in full-and-open federal procurements.

OHSU's federal footprint reflects a hybrid operational model: a large clinical-services segment anchored to the Veterans Health Administration through indefinite delivery contracts for reference laboratory testing, transplant services, physician specialty care (urology, radiation oncology, interventional radiology, perfusionist services), and biostatistical research support; and a substantial research-grant portfolio concentrated in the National Institutes of Health, with particular depth in cancer biology, cardiovascular disease, neurology, infectious disease, and child health. The clinical services align with OHSU's role as the academic medical center for the Portland VA Medical Center (a VHA Level 1A facility), while the grant work reflects investigator-initiated basic and translational research conducted through OHSU's research cores and schools.

Recent federal contract work shows OHSU performing machine learning and biostatistical support for the VA ($620 thousand, September 2026), liver and kidney transplant surgery services ($1.71 million, August 2026), reference laboratory testing ($2.04 million, July 2026), and academic affiliate MRI scans for VA research ($106 thousand, July 2026). On the grant side, OHSU holds active project awards from NIDA for prenatal THC exposure effects on offspring neurodevelopment ($759 thousand), NHLBI for extended continuous positive airway pressure in preterm infants ($737 thousand), NIDDK for AAV-mediated gene therapy for cystinuria ($1.57 million), and NCI for melanoma immunotherapy via ultrasound-responsive nanoparticles ($640 thousand), among dozens of concurrent awards across multiple institutes. The institution also serves as sub-recipient on multi-site clinical trials and translational studies led by Johns Hopkins, Duke University, University of Pennsylvania, and other research centers, typically providing site-specific research coordination, specimen processing, biostatistical analysis, or specialized clinical expertise.

Customer concentration is moderate and segmented. The Department of Veterans Affairs Veterans Integrated Service Network 20 leads by award count (569 awards, $375.3 million potential value) through the portfolio of VA delivery orders for clinical and laboratory services. The National Cancer Institute ranks first by potential value ($500.4 million across 229 awards), followed by VISN 20 clinical services and AHRQ's Evidence-Based Practice Center program ($108.3 million across 102 awards). Together, the top five customer buckets cover 86% of combined potential value. This concentration reflects both OHSU's established role in cancer research and its embedded relationship with the VA's Portland campus, which generates steady renewal orders for reference laboratory, transplant, and physician services.

OHSU's primary contract vehicles are single-award indefinite delivery contracts with Veterans Integrated Service Networks. The largest is the VISN 20 reference laboratory services IDIQ ($9 million ceiling through June 2030), followed by VISN 20 contracts for histocompatibility and immunogenetics testing ($9 million), biostatistics and design services (approximately $743 thousand), and VISN 4 academic affiliate MRI scans ($361 thousand). On the research side, OHSU holds positions on Navy and Department of Health and Human Services vehicles but does not report significant task-order activity on GWACs or government-wide blanket purchase agreements; the institution instead competes for and receives direct project awards from NIH institutes and other civilian agencies.

Activity has grown modestly over the five-year window: 223 awards in 2022 to a peak of 375 in 2024, settling to 332 in 2025 and 120 recorded year-to-date through mid-2026 (a partial-year count). Within the next twenty-four months, 369 awards (combined potential value $43.5 million) reach ultimate completion, signaling recompete pressure in both the VA clinical services portfolio and the NIH grant base as competing projects enter closeout and renewal cycles.

Service Contract Inventory data show SCI-reportable invoicing of $30.1 million across FY2022–FY2024, with 20 to 42 prime contracts per year and an average FTE workforce of 23 to 31 personnel deployed to federal service contracts in those years. The median government-paid hourly rate across SCI records is $120.49/hr, with a range from $7.48/hr (10th percentile, likely representing support or administrative labor) to $449.81/hr (90th percentile, reflecting specialized physician and senior research labor). Across prime contracts, subcontractors account for approximately 5% of total contractor hours, indicating that OHSU builds most of its delivery teams internally; where subcontracting occurs, OHSU names Auburn University (PFAS remediation research), GE Medical Systems Information Technologies (AI algorithms for trauma imaging), and Seattle Children's Hospital (tuberculosis vaccine immunogenetics), among others, typically in support of federal research collaborations or specialized testing.

The institutional footprint spans Portland, Oregon as the primary location, with research operations and clinical services also delivered through Oregon National Primate Research Center (ONPRC, a component of OHSU) and subordinate clinical campuses. OHSU's subsidiary entities include Ohsu Outpatient Clinical Services LLC (a nonprofit operating arm for outpatient delivery), reflecting the institution's structural approach to organizing clinical revenue streams while maintaining tax-exempt status as a public university.